Results: We found that G-CSF was as potent as GM-CSF in enhancing the killing capacity of neutrophils towards neuroblastoma cells. This was observed with in vitro stimulated neutrophils, and with in vivo stimulated neutrophils from both patients with neuroblastoma and healthy donors.

In this in vitro study, we have investigated whether clinically well-established granulocyte colony-stimulating factor (G-CSF) can be a potentially suitable alternative for GM-CSF in the dinutuximab immunotherapy regimen of patients with neuroblastoma.

Jun 6, 2015 · Exogenous G-CSF enhances tumor growth and metastasis in human xenograft and murine neuroblastoma tumor models. In response to G-CSF, STAT3 transcriptionally activates the G-CSF receptor (encoded by CSF3R), creating a CSC sustaining positive-feedback loop.

(D) Neuroblastoma cells secrete colony stimulating factor 1 (CSF-1) to promote TAM recruitment to the tumour microenvironment. Since macrophage infiltration is a poor prognostic indicator in neuroblastoma, anti-CSF antibodies may inhibit CSF-1R activation and cell trafficking.

May 19, 2015 · For patients with neuroblastoma receiving high-dose chemotherapy, doctors also give G-CSF, which causes the bone marrow to produce more white blood cells. This combination therapy has been effective for treating children with high-risk neuroblastoma and has led to improved survival and outcomes.

Sep 30, 2010 · We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk...

Mar 17, 2025 · Combining GM-CSF with dinutuximab enhances antibody-dependent cell-mediated cytotoxicity, ultimately enhancing the anti-neuroblastoma activity of anti-GD2 monoclonal antibody. Besides, GM-CSF is an M1 macrophage polarizing factor, and the expression and release of tumor necrosis factor will also be increased in the environment after ...

Apr 28, 2020 · The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children’s Oncology Group ANBL1221 trial.

Background/objectives: Standard supportive care during induction therapy for high-risk neuroblastoma (HR-NBL) includes primary prophylactic granulocyte colony-stimulating factor (G-CSF) aimed at limiting duration of neutropenia, reducing …

Exogenous G-CSF enhances tumor growth and metastasis in human xenograft and murine neuroblastoma tumor models. In response to G-CSF, STAT3 transcriptionally activates the G-CSF receptor (encoded by CSF3R), creating a CSC sustaining positive-feedback loop.